What Corcept Therapeutics Does & How It Makes Money (CORT)

Updated October 2026 · reflects Corcept Therapeutics's latest reported financials

Biopharma company developing cortisol-modulating drugs for Cushing's and other disorders. Corcept makes money by selling its approved prescription drug Korlym in the United States.

How Corcept Therapeutics makes money

Corcept makes money by selling its approved prescription drug Korlym in the United States. That revenue helps pay for clinical development of its pipeline of selective cortisol modulators.

What Corcept Therapeutics does

Corcept Therapeutics is a U.S. biopharmaceutical company, founded in 1998 and based in Redwood City, California, that focuses on cortisol modulation. Its approved product, Korlym, is an oral drug for hyperglycemia caused by excess cortisol in adults with endogenous Cushing's syndrome who also have type 2 diabetes or glucose intolerance, and who have failed surgery or can't have it. The company's growth story depends on its proprietary pipeline of selective cortisol modulators. Relacorilant is being developed for hypercortisolism, miricorilant is in a Phase 1b trial for metabolic dysfunction-associated steatohepatitis (MASH), and dazucorilant targets ALS. The company also works across endocrine, cancer, metabolic, and neurologic diseases.

Products & services

• Korlym
• relacorilant
• miricorilant
• dazucorilant
• nenocorilant

What is Corcept Therapeutics worth?

On an owner-earnings DCF, Corcept Therapeutics's most-likely value is about $62 versus a recent price near $121 (49% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$16) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.

Related companies

Cytokinetics (CYTK) · Protagonist Therapeutics (PTGX) · Roivant Sciences (ROIV) · Collegium Pharmaceutical (COLL) · Regeneron Pharmaceuticals (REGN)